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DOI 10.1016/j.ccr.2009.11.021SUMMARYInhibitor-of-Apoptosis (IAP) proteins contribute to tumor progression, but the requirements of this pathway
are not understood. Here, we show that intermolecular cooperation between XIAP and survivin stimulates
tumor cell invasion and promotes metastasis. This pathway is independent of IAP inhibition of cell death.
Instead, a survivin-XIAP complex activates NF-kB, which in turn leads to increased fibronectin gene expres-
sion, signaling by b1 integrins, and activation of cell motility kinases FAK and Src. Therefore, IAPs are direct
metastasis genes, and their antagonists could provide antimetastatic therapies in patients with cancer.INTRODUCTION
Metastasis, which is the dissemination of tumor cells to distant
organs (Nguyen and Massague, 2007), heralds a nearly invari-
ably fatal phase of epithelial malignancies, with few, if any,
therapeutic options. This process reflects the acquisition of
multiple molecular traits by tumor cells, including the ability to
counteract the cell death program initiated by detachment
from the extracellular matrix, or anoikis (Frisch and Screaton,
2001), proteolyze and migrate through basement membranes,
invade blood or lymphatic vessels, and proliferate in unrelated
microenvironments (Weigelt et al., 2005). The exact timing of
these processes is unknown, andwhether they reflect sequential
adaptive changes (Scheel et al., 2007) or selection of specially
endowed clones (Talmadge, 2007) has been debated. However,
one invariable feature of the metastatic process is deregulated
gene expression, which affects sequential stages of tumor cell
invasion, organ tropism, and growth at distant sites (Nguyen
and Massague, 2007). A potential loss of ‘‘metastasis-
suppressor’’ genesmay also contribute to this pathway (Stupack
et al., 2006).
Although the molecular requirements of metastasis remain
largely elusive, ‘‘outside-in’’ signaling initiated by ligation of
integrin cell surface receptors (Ginsberg et al., 2005) with extra-
cellular matrix proteins (Juliano et al., 2004) likely plays a pivotalSIGNIFICANCE
Metastasis is a hallmark of tumor progression, characterized b
a better understanding of this process, which is often char
therapies do not presently exist, and patients with dissem
inhibitor-of-apoptosis (IAP) molecules function as direct activ
dently of their roles in cytoprotection. IAP antagonists are now
may provide first-in-class antimetastatic therapies for patientsrole in this process. As an abundant constituent of the extracel-
lular matrix, fibronectin bindsmultiple integrins (Cukierman et al.,
2002), resulting in the activation of focal adhesion kinase (FAK)
(Sieg et al., 2000), Src (Yeatman, 2004), and Akt (Irie et al.,
2005), as well as modulation of small GTPases of the Rho family
(Nobes and Hall, 1995). In response to these signals, cells
remodel their actin cytoskeleton (Juliano et al., 2004), express
matrix metalloproteinases (Han et al., 2006), become migratory
(Livant et al., 2000), invade basement membranes (Gaggioli
et al., 2007), and acquire the ability to resist apoptosis (Fornaro
et al., 2003).
In this context, aberrantly increased cell survival is an invari-
able requirement of metastasis (Mehlen and Puisieux, 2006)
and is typically contributed via deregulated expression of Bcl-2
(Cory and Adams, 2002) or inhibitor-of-apoptosis (IAP) (Sriniva-
sula and Ashwell, 2008) cytoprotective proteins. However,
some of these molecules, especially IAPs, have recently
emerged as broader regulators of cellular homeostasis, with
functions extending beyond apoptosis inhibition (Srinivasula
and Ashwell, 2008). For instance, IAP family protein XIAP has
been linked to the activation of multiple gene expression
networks, including Smad/TGFb (Birkey Reffey et al., 2001),
JNK (Sanna et al., 1998), or NF-kB (Hofer-Warbinek et al.,
2000; Lu et al., 2007), whereas survivin plays essential roles
in mitosis, the cellular stress response, and developmentaly the dissemination of cancer cells to distant organs. Despite
acterized by deregulated gene expression, antimetastatic
inated disease have limited options. We now show that
ators of tumor cell motility and metastasis genes indepen-
being tested in early phase clinical trials, and these agents
with cancer.
Cancer Cell 17, 53–64, January 19, 2010 ª2010 Elsevier Inc. 53
Figure 1. IAP-Mediated Tumor Cell Invasion
(A and B) Breast adenocarcinoma MDA-MB-231
(A) or prostate adenocarcinoma PC3 (B) cells
transfected with control (Ctrl) or survivin (SVV)–
directed or XIAP-directed siRNA were analyzed
by western blotting after 48 hr. Asterisks indicate
nonspecificity.
(C–E) The indicated siRNA transfected cell types
were analyzed for invasion through Matrigel-
coated Transwell inserts after 6 hr by DAPI staining
(C) and were quantified (D and E). Scale bars,
200 mm (MDA-MB-231) and 100 mm (PC3).
(F) PC3 cells were transfected with control (Ctrl) or
cIAP1-directed siRNA and were analyzed by PCR
(left) and Matrigel invasion after 6 hr (right).
(G) MCF-7 or MCF-7 SVV cells (clones no. 1 and
no. 2) were analyzed for Matrigel invasion after
6 hr by DAPI staining (left) and were quantified
(right). Scale bars, 200 mm. For (D)–(G), data are
the mean ± SD of duplicates of a representative
experiment out of at least two independent
determinations. See also Figure S1.
Cancer Cell
Survivin-XIAP Signaling in Metastasispathways of gene expression (Altieri, 2008). How these multiple
functions of IAPs work together in cellular homeostasis is
unclear, and the exact contribution of these noncytoprotective
mechanisms, if any, to tumor progression has not been investi-
gated. In this study, we investigated whether IAP signaling
affected metastasis as a key determinant of unfavorable disease
outcome.
RESULTS
IAP-Mediated Tumor Cell Invasion
To begin investigating a role of IAPs in tumor progression, we
first silenced the expression of XIAP or survivin in invasive breast
adenocarcinoma MDA-MB-231 (Figure 1A) or prostate adeno-
carcinoma PC3 (Figure 1B) cells. Transfection of these cells
with XIAP- or survivin-directed small interfering RNA (siRNA)
suppressed the expression of the intended IAP protein, but not
vice versa, whereas a nontargeting siRNA had no effect (Figures
1A and 1B). Under these conditions, survivin or XIAP knockdown
inhibited MDA-MB-231 or PC3 cell invasion through Matrigel
inserts, compared with control transfectants (Figures 1C and
1D). Similar results were obtained with siRNA silencing of54 Cancer Cell 17, 53–64, January 19, 2010 ª2010 Elsevier Inc.these IAPs in colorectal adenocarcinoma
HCT116 cells, whereas a nontargeting
siRNA had no effect (Figure 1E). In addi-
tion, siRNA knockdown of a different
IAP, cIAP1, also abolished Matrigel inva-
sion of PC3 cells (Figure 1F), suggesting
that tumor cell invasion was a general
property of multiple IAPs.
Next, we examined the specificity of
this pathway, and we used clones of non-
invasive breast adenocarcinoma MCF-7
cells stably transfected with survivin.
These cells, designated MCF-7 SVV,
express 2- to 3-fold increased survivin
levels, compared with those of MCF-7cells (Figure S1A available online), and thus are similar to more
invasive cell types (Figure 1A). Compared with parental cultures,
MCF-7 SVV cells did not exhibit changes in cell proliferation
(Figure S1B), adhesion to fibronectin- or collagen-containing
substrates (Figure S1C), remodeling of the actin cytoskeleton
(Figure S1D), or expression of various integrins (Figure S1E).
Instead, MCF-7 SVV cells became highly migratory on collagen-
coated inserts, compared with parental cultures (Figure S1F), or
MCF-7 cells transfected with empty plasmid (data not shown).
Consistent with this finding, two independent clones of MCF-7
SVV cells showed markedly enhanced invasion through Matri-
gel-coated inserts, whereas nontransfected MCF-7 cells were
not invasive (Figure 1G).
Confirming the specificity of IAPs in this response, siRNA
knockdown of XIAP or survivin in MCF-7 SVV cells (Figure 2A)
suppressed Matrigel invasion, whereas a nontargeting siRNA
had no effect (Figure 2B). Conversely, cell viability was only mini-
mally affected after XIAP (7%) or survivin (14.2%) silencing, com-
pared with control transfectants (4.8%). cIAP1 knockdown also
reduced Matrigel invasion of MCF-7 SVV cells from 61.5 ± 11.1
(control siRNA) to 11.3 ± 1.6 invaded cells per field (p = 0.0003;
n = 10). As an independent approach, we transduced MCF-7
Figure 2. IAP Targeting Inhibits Tumor Cell
Invasion
(A) MCF-7 SVV cells transfected with control (Ctrl)
or survivin (SVV)–directed or XIAP-directed siRNA
were analyzed by western blotting.
(B) MCF-7 SVV cells (clone no. 1) transfected with
the indicated siRNA were analyzed for Matrigel
invasion after 6 hr by DAPI staining (left) and
were quantified (right). Scale bars, 200 mm.
(C) MCF-7 SVV cells were transduced with
pAd-GFP or pAd-T34A/C84A survivin mutant and
were imaged after 24 hr for GFP expression (top)
or DAPI staining of Matrigel invasion (bottom).
Invaded cells were quantified after 6 hr (right).
Scale bars, 200 mm.
(D and E) MCF-7 SVV cells with stable shRNA
knockdown of XIAP (MCF-7 SVV-XIAP KD; clones
no. 1 and no. 2) were analyzed by western blotting
(D) andquantified forMatrigel invasionafter 6hr (E).
(F and G) Wild-type (WT) or XIAP/ HCT116 cells
were analyzed by western blotting (F) and were
characterized for Matrigel invasion after 6 hr by
DAPI staining (G, left), and quantified (G, right).
Scale bars, 200 mm.
(H) XIAP/ HCT116 cells were stably transfected
with WT XIAP or D143A/W310A XIAP mutant and
were analyzed by western blotting. Wild-type
(XIAP+/+) HCT116 cells were used as a control.
(I) XIAP/ HCT116 cells stably expressing WT
XIAP or XIAP D143A/W310A mutant (clones no.
123 and no. 126) were quantified for Matrigel inva-
sion after 6 hr by DAPI staining. For (B), (C), (E),
(G), and (I), data are the mean ± SD of duplicates
of a representative experiment out of at least two
independent determinations. See also Figure S2.
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negative survivin Cys84Ala/Thr34Ala mutant (pAd-T34A/C84A).
Although expressed at comparable levels as pAd-GFP by
fluorescence microscopy (Figure 2C, top), this survivin mutant
abolished Matrigel invasion (Figure 2C), whereas cell cycle
kinetics or cell viability were not affected within the same time
interval (Figure S2A). Finally, we stably silenced the expression
of XIAP in MCF-7 SVV cells using a lentivirus construct encoding
XIAP-directed short hairpin RNA (Figure 2D). Independently
established clones of these cells, designated MCF-7 SVV-XIAP
KD, showed marked inhibition of Matrigel invasion, compared
with control cultures (Figure 2E).
To independently validate these findings, we next examined
a second tumor model, HCT116 cells, in which siRNA silencing
of XIAP or survivin suppressed Matrigel invasion (Figure 1E).
Consistent with this finding, homozygous deletion of XIAP
(XIAP/) in HCT116 cells (Figure 2F) completely abolished
tumor cell invasion, whereas wild-type HCT116 cells (XIAP+/+)
were highly invasive (Figure 2G).
IAP Antiapoptotic Functions Are Not Required
for Tumor Cell Invasion
To test whether IAP cytoprotection contributed to tumor cell inva-
sion, we next used amodel of rat insulinoma INS-1 cells. Previous
studies showed that stable transfection of survivin in these cells
(INS-1 SVV) (Figure S2B) does not inhibit apoptosis because of
the lackofmitochondrial import (Dohi et al., 2007). INS-1SVVcellsreadily invaded through Matrigel inserts, whereas control INS-1
transfectants were not invasive (Figure S2C). In addition, stable
transfection of antiapoptotic Bcl-2 in INS-1 cells (Figure S2B),
which promoted exponential tumor growth in vivo (Dohi et al.,
2007), did not mediate tumor cell invasion (Figure S2C). We next
asked whether a similar paradigm applied to XIAP, and we stably
transfected XIAP/ HCT116 cells with an Asp143Ala/Trp310Ala
XIAP double mutant (D143A/W310A) that does not bind caspase
3 (D143A mutation) or caspase 9 (W310A mutation), and is thus
devoid of antiapoptotic functions (Lewis et al., 2004) (Figure 2H).
Independent clones of this cell line robustly invaded through Ma-
trigel inserts, quantitatively indistinguishably from XIAP/ cells
reconstituted with wild-type (i.e., antiapoptotic) XIAP (Figure 2I).
IAP Induction of Fibronectin Regulates
Tumor Cell Invasion
To begin understanding how IAPs promote tumor cell invasion,
we next looked at the gene expression profile of model MCF-7
SVV cells, in which expression of survivin alone was sufficient
to confer an invasive phenotype (Figure 1F). Microarray analysis
of these cells revealed a significant up-regulation of multiple
extracellular matrix proteins implicated in cell invasion, including
lumican (4106-fold), fibronectin (334-fold), and laminin a4
(105-fold). Accordingly, MCF-7 SVV cells exhibited a >120-fold
upregulation of fibronectin mRNA, as determined by real-time
PCR (Figure 3A), and increased fibronectin promoter activity,
as determined by luciferase reporter assay (Figure 3B),Cancer Cell 17, 53–64, January 19, 2010 ª2010 Elsevier Inc. 55
Figure 3. IAP Induction of Fibronectin
(A) RNAwas amplified for the indicated gene prod-
ucts and was normalized to GAPDH expression.
Fn, fibronectin; Lam 5, laminin 5; CollA1, collagen
A1; Col IVA2, collagen IV A2.
(B) Cells transfected with pcDNA or a 1.9 kb fibro-
nectin promoter-luciferase construct (pGL-Fib)
were analyzed after 24 hr for b-galactosidase-
normalized luciferase activity. RLU, relative lucif-
erase units.
(C)Cell extractswere analyzedbywesternblotting.
(D) Conditioned media collected after 48 hr was
normalized per cell number and analyzed by
western blotting.
(E) Cell migration on uncoated Transwell inserts
was analyzed by DAPI staining (left) and quantified
(right). Scale bars, 200 mm.
(F) Microarray data sets of two breast cancer
patient series were analyzed for expression of
survivin and fibronectin (Fn) in tumor (T) versus
normal (N) tissues.
(G) MCF-7 SVV cells transfected with control (Ctrl)
or fibronectin (Fn)-directed siRNA were analyzed
after 48 hr by western blotting. Scale bars, 200 mm.
(H) siRNA-transfected cells as in (G) were
analyzed for Matrigel invasion after 6 hr by DAPI
staining (left) and were quantified (right). Scale
bars, 200 mm. ***p = 0.0006.
(I) MCF-7 SVV cells were incubated with
nonbinding IgG or a function-blocking antibody
to b1 integrin (b1) and were characterized for
Matrigel invasion after 6 hr by DAPI staining (left) and were quantified (right). Scale bars, 200 mm. For (A), (B), (E), (H), and (I), data are the mean ± SD of duplicates
of a representative experiment out of at least two independent determinations. For (F), data are shown as box plots, where whiskers are the minimum and
maximum, and the box is the upper and lower quartile. See also Figure S3.
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collagen type 5 a2 mRNAs were also increased in MCF-7 SVV
cells, albeit less prominently, whereas expression of laminin 5
was not significantly different, compared with parental cultures
(Figure 3A). Consistent with these data, MCF-7 SVV cells ex-
hibited dramatically increased endogenous fibronectin protein
content, as determined by fluorescence microscopy (data not
shown) and western blotting (Figure 3C). This newly produced
fibronectin was released in the conditioned medium of MCF-7
SVV cells (Figure 3D) and was sufficient to support tumor cell
migration on Transwell inserts in the absence of exogenous
substrate (Figure 3E). In contrast, parental MCF-7 cells did not
migrate in the absence of substrate (Figure 3E). Similar results
were obtained with an unrelated cell type, because INS-1 cells
stably transfected with survivin (INS-1 SVV) also exhibited a
7- to 8-fold increased fibronectin mRNA (Figure S3A) and protein
(Figure S3B). In contrast, INS-1 Bcl-2 transfectants, or cells
transfected with a control plasmid, showed no modulation of
fibronectin levels (Figures S3A and S3B).
Using breast cancer as a model, we next asked whether a
relationship between IAP and fibronectin expression existed in
human tumors. Analysis of two independent patient cohorts
revealed that survivin and fibronectin were coordinately
increased in tumor versus normal tissues (Figure 3F). Similarly,
invasive breast adenocarcinoma cell lines SUM159 and
HBL100 contained high levels of endogenous fibronectin (Fig-
ure S3C), suggesting that its expression segregated with the
tumor cell population, rather than stromal cells.56 Cancer Cell 17, 53–64, January 19, 2010 ª2010 Elsevier Inc.Finally, we tested whether fibronectin produced and released
by IAP-expressing cells contributed to tumor cell invasion. Here,
siRNA knockdown of fibronectin in MCF-7 SVV cells (Figure 3G)
significantly inhibited Matrigel invasion, compared with control
transfectants (Figure 3H). Similarly, preincubation of MCF-7
SVV cells with a function-blocking antibody to b1 integrins,
which comprise the main fibronectin receptor on these cells,
abolished tumor cell invasion, whereas nonbinding IgG was
ineffective (Figure 3I).
IAP Intermolecular Cooperation Activates NF-kB
We next asked how IAP may transcriptionally up-regulate fibro-
nectin and focused on a potential role of NF-kB in this response.
For these experiments, we stably transfected survivin in wild-
type or XIAP/ mouse embryonic fibroblasts that have very
low levels of endogenous survivin (Figure S4A). Expression of
survivin in XIAP+/+ cells (clones no. 44 and no. 68) resulted in
nuclear translocation of p65 NF-kB (Figure 4A) and increased
NF-kB promoter activity, quantitatively similar to TNFa stimula-
tion (Figure 4B). In contrast, survivin expression in XIAP/ cells
(clones no. 2 and no. 5) had no effect on NF-kB translocation
(Figure 4A) or NF-kB promoter activity (Figure 4B). By use of
EMSA, a radiolabeled NF-kB probe bound to nuclear extracts
in XIAP+/+ cells transfected with survivin, which was supershifted
by an antibody to p65 NF-kB, but not IgG (Figure 4C). Con-
versely, expression of survivin in a XIAP/ background had
minimal effect on NF-kB-protein complexes (Figure 4C). In
‘‘add-back’’ experiments, transfection of survivin-expressing
Figure 4. NF-kB Induction of Fibronectin
Mediates IAP Tumor Cell Invasion
(A) Nuclear extracts from WT (clones no. 44 and
no. 68) or XIAP/ (clones no. 2 and no. 5) mouse
embryonic fibroblasts stably transfected with sur-
vivin were analyzed by western blotting.
(B) Survivin-expressingWT or XIAP/ clones as in
(A) were analyzed for b-galactosidase-normalized
NF-kB-luciferase reporter activity. TNFa-stimu-
lated cells were used as a control. **p = 0.006.
RLU, relative luciferase units.
(C) Nuclear extracts from WT or XIAP/ clones
expressing survivin as in (A) were incubated
with a 32P-labeled NF-kB probe in the presence
of IgG or an antibody to p65 NF-kB, followed by
autoradiography. In reconstitution experiments,
XIAP/ cells were transfected with wild-type
XIAP or RING-less XIAP (RING-D). Arrowhead
indicates supershift.
(D) INS-1 clones stably transfected with the indi-
cated survivin mutant were analyzed for b-galac-
tosidase-normalized NF-kB luciferase promoter
activity, with or without TNFa.
(E) Extracts from MCF-7 cells incubated with
recombinant survivin (SVV), XIAP, or IkBa were
analyzed bywestern blotting. Bottom panel shows
densitometric quantification of protein bands.
(F) Unstimulated or TNFa (ng/ml)-stimulated cells
were analyzed by western blotting.
(G) MCF-7 SVV cells transfected with control (Ctrl)
or p65 NF-kB-directed siRNA were analyzed
after 48 hr by western blotting. Asterisks indicate
nonspecificity.
(H) MCF-7 SVV cells transfected with control (Ctrl),
survivin (SVV)-directed, or XIAP-directed siRNA
were analyzed by western blotting.
(I) MCF-7 SVV cells transfected with control (Ctrl)
or p65 NF-kB-directed siRNA, or, alternatively,
pcDNA or IkBa mutant (IkBa-Mut), were analyzed for Matrigel invasion after 6 hr by DAPI staining (left) and were quantified (right). Scale bars, 200 mm.
***p < 0.0001. Mean ± SD of duplicates of a representative experiment out of at least two independent determinations. For (B) and (D), data are the mean ±
SEM of triplicates of two independent determinations. See also Figure S4.
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NF-kB complexes, whereas a RING-less XIAP mutant (RING-D)
was ineffective (Figure 4C). Similarly, INS-1 cells stably trans-
fected with a survivin S20A mutant, which constitutively binds
XIAP (Dohi et al., 2007), strongly activated NF-kB promoter
activity (Figure 4D). In contrast, INS-1 cells expressing a survivin
S20E mutant that does not bind XIAP (Dohi et al., 2007) showed
reduced NF-kB promoter activity with or without TNFa (Fig-
ure 4D). Finally, siRNA knockdown of survivin inMCF-7 SVV cells
significantly reduced NF-kB promoter activity, compared with
control transfectants (Figure S4B). Therefore, a survivin-XIAP
complex (Dohi et al., 2007) activates NF-kB.
With regard to the mechanisms of NF-kB activation under
these conditions, the addition of recombinant XIAP to MCF-7
cell extracts promoted the phosphorylation of the negative
NF-kB regulator, IkBa (Figure 4E). However, the combination
of survivin plus XIAP further enhanced IkBa phosphorylation
(Figure 4E), in a reaction stabilized by the proteasome inhibitor,
lactacystin (Figure S3C). Conversely, a Val80Asp (V80D) XIAP
mutant that does not activate NF-kB (Lu et al., 2007) had no
effect on IkBa phosphorylation, with or without lactacystin
(Figure S4C). Accordingly, reconstitution of XIAP/ cells withwild-type XIAP, but not V80D XIAP mutant, stimulated NF-kB
promoter activity with and without TNFa (Figure S4D).
NF-kB Induction of Fibronectin Contributes
to IAP-Mediated Tumor Cell Invasion
Consistent with a bona fide NF-kB target gene, TNFa stimulation
of MCF-7 or MCF-7 SVV cells resulted in increased fibronectin
expression, albeit more prominently in survivin transfectants
(Figure 4F). Conversely, siRNA knockdown of p65 NF-kB
(Figure S4E) suppressed endogenous fibronectin expression in
MCF-7 SVV cells, compared with control siRNA (Figure 4G).
Similarly, siRNA silencing of survivin or XIAP also comparably
suppressedfibronectinexpression inMCF-7SVVcells (Figure4H).
Functionally, siRNA knockdown of p65 NF-kB (Figure S4E), or
expression of a phosphorylation-defective IkBa ‘‘super-
repressor’’ mutant (Figure S4F), inhibited Matrigel invasion of
MCF-7 SVV cells, comparedwith control transfectants (Figure 4I).
Signaling Requirements of IAP-Mediated
Tumor Cell Invasion
To identify downstream effectors of IAP-directed tumor cell
invasion, we next focused on kinase cascades implicated inCancer Cell 17, 53–64, January 19, 2010 ª2010 Elsevier Inc. 57
Figure 5. IAP Activation of Cell Motility
Kinases
(A–D) Adherent cells were analyzed after 48 hr by
western blotting for phosphorylation/expression
of FAK (A), Src (B), Akt (C), or ERK1,2 (D).
(E) MCF-7 SVV cells with stable shRNA knock-
down of XIAP (MCF-7 SVV-XIAP KD; clones no.
1 and no. 2) were analyzed by western blotting.
(F) INS-1 cells stably transfected with wild-type
survivin (SVV) or survivin S20E mutant (clones
no. 2 and no. 6) were analyzed by western blotting.
(G) MCF-7 SVV cells transfected with pcDNA or
FAK dominant negative FRNK mutant were
analyzed for Matrigel invasion after 6 hr by DAPI
staining (left) and were quantified (right). Scale
bars, 200 mm. ***p < 0.0001.
(H) MCF-7 SVV cells treated with the indicated
pharmacologic inhibitors were quantified for
Matrigel invasion after 6 hr.
(I) MCF-7 SVV cells treated with the Src inhibitor
SU6656 (25–50 mM) were quantified for Matrigel
invasion after 6 hr.
(J) MCF-7 SVV cells were incubated with vehicle
(DMSO) or the indicated Src inhibitors and were
analyzed for DNA content after 24 hr by propidium
iodide staining and flow cytometry. The per-
centage of cells in the G1 or G2/M phase of the
cell cycle is indicated. For (G), (H), and (I), data
are themean ±SDof duplicates of a representative
experiment out of at least two independent deter-
minations. See also Figure S5.
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exhibited constitutive phosphorylation of FAK on Tyr397
(Figure 5A) andSrconTyr418 (Figure 5B), comparedwithparental
MCF-7 cells. In contrast, phosphorylated Akt (Figure 5C) or
ERK1,2 (Figure 5D) was comparable in the two cell types, and
total kinase protein content was unchanged (Figures 5A–5D).
Stable knockdown of XIAP inMCF-7 SVV cells (MCF-7 SVV-XIAP
KD) reducedFAKandSrcphosphorylationandsignificantlyatten-
uated endogenous fibronectin content in these cells (Figure 5E),
reinforcing a role of IAP intermolecular cooperation in this
response. Similarly, Src was constitutively phosphorylated in
INS-1 cells expressing wild-type survivin but not a survivin S20E
mutant (Figure 5F) that does not bind XIAP (Dohi et al., 2007).
Functionally, targeting FAKwith a truncateddominant negative
FAK protein, FRNK (Figure S5A), inhibited MCF-7 SVV cell inva-
sion through Matrigel (Figure 5G). Similarly, two unrelated phar-
macologic antagonists of Src, PP2 (Figure 5H) or SU6656
(Figure 5I), suppressed Matrigel invasion of MCF-7 SVV
(Figure 5H and 5I) or MDA-MB-231 (Figure S5B) cells without
affecting cell viability or cell cycle kinetics (Figure 5J). In contrast,
pharmacologic antagonists of MEK (PD98059 or U0126) or PI3
kinase (LY294002) hadnoeffect on IAP-mediated tumor cell inva-
sion (Figure 5H). Confirming their activity, all inhibitors abolished
the phosphorylation of their intended target kinase (Figure S5C).
IAP Protection from Anoikis
The ability of tumor cells to remain viable when detached from
the extracellular matrix may contribute to metastasis, and58 Cancer Cell 17, 53–64, January 19, 2010 ª2010 Elsevier Inc.a role of IAP in this response was next investigated. MCF-7 cells
forced to remain in suspension showed time-dependent anoikis
(Figure 6A) and release of apoptogenic Smac from mitochondria
(Figure 6B). In contrast, MCF-7 SVV cells were protected from
anoikis (Figure 6A) and exhibited reduced release of Smac
from mitochondria (Figure 6B). When attached to substrate, no
differences were observed in background levels of Smac release
between MCF-7 and MCF-7 SVV cells (Figure 6B). Survivin
silencing by siRNA reversed cytoprotection of MCF-7 SVV cells
in suspension (Figure S6) and strongly enhanced anoikis (Fig-
ure 6C). Conversely, survivin knockdown in attached MCF-7
SVV cells (Figure S6) did not significantly reduce cell viability
within the same time interval (Figure 6C).
Although survivin inhibited anoikis (Figure 6C), MCF-7 and
MCF-7 SVV cells grew comparably as colonies in soft agar
(Figure 6D), and MCF-7 SVV cells in suspension did not release
survivin from mitochondria into the cytosol (Figure 6E), which is
required for cytoprotection (Dohi et al., 2007). Instead, MCF-7
SVV cells in suspension, but not parental MCF-7 cells, exhibited
constitutive phosphorylation of FAK and Src (Figure 6F), which
has been implicated in protection from anoikis (Bouchard
et al., 2008). In addition, siRNA knockdown of fibronectin
(Figure 6G) or its receptor, b1 integrin (Figure 6H), suppressed
FAK and Src phosphorylation in MCF-7 SVV cells in suspension.
IAP-Dependent Metastasis
For these studies, we used a liver metastasis model, in
which tumor cells are injected directly into the spleen of
Figure 6. IAP Suppression of Anoikis
(A) Cells were maintained in suspension using
ultra-low (U-L) attachment plates and were
analyzed at the indicated time intervals by propi-
dium iodide staining and flow cytometry. The
percentage of cells with hypodiploid (apoptotic)
DNA content is indicated.
(B) Cytosolic extracts of cultures maintained
attached or in suspension (U-L) were analyzed
by western blotting.
(C) Cultures maintained attached (A) or in suspen-
sion (U-L) were transfected with control (Ctrl) or
survivin (SVV)–directed siRNA and were analyzed
by phase contrast microscopy (left) and quantified
for nuclear morphology of apoptosis after 48 hr
(right). Scale bars, 200 mm.
(D) Cells were plated at the indicated numbers in
semisolid medium, and colonies were scored after
2 weeks by light microscopy.
(E) Mitochondria (top) or cytosolic (bottom)
extracts of cultures attached or in suspension
(U-L) were analyzed by western blotting.
(F) Cultures in suspension were analyzed by
western blotting.
(G) MCF-7 SVV cells transfected with control (Ctrl)
or fibronectin (Fn)–directed siRNA in suspension
were analyzed by western blotting.
(H) Cells transfected with control (Ctrl) or b1 integ-
rin (b1)–directed siRNA were analyzed by western
blotting. For (C) and (D), data are the mean ± SD of
duplicates of a representative experiment out of at
least two independent determinations. See also
Figure S6.
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Survivin-XIAP Signaling in Metastasisimmunocompromised SCID/beige mice, followed by splenec-
tomy after 24 hr to avoid potential interference of primary tumor
growth on liver metastasis. Splenic injection of MCF-7 cells did
not result in significant liver metastasis (Figure 7A and Fig-
ure S7A), and organs in this group were histologically normal
(Figure 7B). In contrast, MCF-7 SVV cells reconstituted in the
same model gave rise to extensive metastatic localization of the
liver (Figure 7A and Figure S7A), with foci of viable epithelial cells
in the liver parenchyma (Figure 7B and Figure S7B). Liver metas-
tases of MCF-7 SVV cells stained for phosphorylated FAK in vivo
(Figure S7C), which is consistent with a potential role of activated
FAK in this pathway. In contrast, stable knockdown of XIAP in
MCF-7 SVV cells (MCF-7 SVV-XIAP KD) completely suppressed
their ability to metastasize to the liver (Figure 7A and Figure S7A).
As an independent tumor model, intrasplenic injection of
wild-type XIAP+/+ HCT116 cells resulted in massive metastatic
colonization of the liver, with nearly complete substitution of
the hepatic parenchyma by the tumor cell population (Figure 7C).
In contrast, XIAP/ cells did not significantly metastasize to the
liver (Figure 7C). Quantification of liver metastasis revealed that
HCT116 cells expressing wild-type XIAP produced a >2-fold
increase in liver weight, compared with noninjected animals or
mice reconstituted with XIAP/ cells (Figure S7D).
We have shown above that IAP cytoprotection is not required
for tumor cell invasion in vitro, and we next asked whether asimilar paradigm applied to metastatic dissemination in vivo.
XIAP/ HCT116 cells stably transfected with D143A/W310A
XIAP double mutant devoid of antiapoptotic function (Lewis
et al., 2004) produced extensive liver metastasis (p = 0.038 vs.
normal liver; Figure S7D), quantitatively indistinguishable from
XIAP+/+ HCT116 cells (Figure 7C; not significant; Figure S7D).
Similarly, INS-1 clones stably transfected with wild-type survivin,
which is not cytoprotective in these cells (Dohi et al., 2007), gave
rise to systemic disease in SCID/beige mice, as judged by
time-dependent decrease in blood glucose (Figure 7D), a
biomarker of aberrant insulin production by insulinoma cells.
This was associated with prominent metastatic dissemination
of insulin-producing INS-1 cells to the liver (Figures 7E and 7F).
In contrast, animals injected with INS-1 cells expressing antia-
poptotic Bcl-2 did not show changes in blood glucose levels
(Figure 7D) and generated negligible liver metastasis (Figure 7F
and Figure S7E). Previously, these cells promoted exponential
growth of superficial tumors in SCID/beige mice, validating the
activity of Bcl-2 (Dohi et al., 2007).
DISCUSSION
In this study, we have shown that intermolecular cooperation
between IAP proteins, XIAP and survivin, promotes tumor cell
invasion in vitro and metastatic dissemination in vivo. ThisCancer Cell 17, 53–64, January 19, 2010 ª2010 Elsevier Inc. 59
Figure 7. IAP-Mediated Metastasis In Vivo
(A) MCF-7, MCF-7 SVV, or MCF-7 SVV cells carrying stable knockdown of XIAP (MCF-7 SVV-XIAP KD) stably transfected with luciferase were injected in
the spleens of SCID/beige mice and were analyzed for metastatic tumor growth at the indicated time intervals, by bioluminescence imaging.
(B) Livers from representative animals (#) reconstituted as indicated were harvested at day 11 and were analyzed by hematoxylin-eosin (H&E) staining and
light microscopy. Arrows indicate metastatic foci. Scale bars, 100 mm and 500 mm.
(C) XIAP+/+, XIAP/, or XIAP D143A/W310A mutant HCT116 cells were injected in the spleens of SCID/beige mice, and resected livers were examined
macroscopically after 2 weeks.
(D) SCID/beige mice reconstituted with INS-1 cells stably transfected with survivin or Bcl-2 were analyzed for blood glucose levels.
(E) Livers of animals reconstituted with INS-1 cells transfected with survivin were stained by H&E or insulin. IgG, nonbinding antibody. Arrows indicate metastatic
foci. Scale bars, 500 mm.
(F) Metastatic foci of INS-1 cells were counted blindly in four independent microscopy fields of serial liver sections harvested from the indicated animal groups.
*p = 0.017–0.025. For (D) and (F), data are the mean ± SEM. See also Figure S7.
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Instead, these molecules orchestrate a cellular network in dispa-
rate tumor cell types centered on NF-kB activation, transcrip-
tional up-regulation of fibronectin, autocrine/paracrine signaling
by b1 integrins, and constitutive phosphorylation (i.e., activation)
of cell motility kinases FAK and Src (Figure 8). These data identify
IAPs as direct metastasis genes, opening prospects for thera-60 Cancer Cell 17, 53–64, January 19, 2010 ª2010 Elsevier Inc.peutic intervention against these targets in patients with
advanced and disseminated disease.
Beyond their roles in cytoprotection, it is now clear that IAPs
function as broader regulators of cellular homeostasis, interca-
lated in cell division, metabolism, and activation of multiple
intracellular signaling pathways, including NF-kB, TGFb, or
JNK (Srinivasula and Ashwell, 2008). The data presented here
Figure 8. Schematic Mechanistic Model of IAP-Induced Metastasis
See text for additional details.
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Survivin-XIAP Signaling in Metastasisposition IAP signaling in the control of multiple, independent
stages of the metastatic cascade conferring a general motility
phenotype to tumor cells, unaffected by substrate attachment,
competent to withstand anoikis, and ideal to support coloniza-
tion of distant organs (Figure 8). In this context, a role of IAPs
in cell motility may be evolutionary conserved, because a
Drosophila IAP homolog has been implicated in cytoskeletal re-
arrangement and cell migration (Geisbrecht and Montell, 2004)
via activation of small GTPase signaling (Oshima et al., 2006).
However, whether a similar paradigm extended to mammalian
cells, especially tumor cells, has been controversial, and a recent
report suggested that silencing of IAPs actually increased tumor
cell motility, potentially through enhanced c-Raf stability (Dogan
et al., 2008). It is possible that the discrepancy between these
results (Dogan et al., 2008) and the data presented here may
reflect context-specific utilization of activated c-Raf for cell
motility, as opposed to cell invasion. On the other hand, c-Raf
has been known to inhibit (Slack et al., 1999), rather than
promote (Dogan et al., 2008), cell migration, potentially by
suppressing integrin activation (Hughes et al., 1997).
Here, the upstream step in IAP-mediated metastasis involved
activation of NF-kB-dependent gene expression. A link between
IAPs, mostly XIAP, and NF-kB activity (Srinivasula and Ashwell,
2008) has been previously associated with ubiquitination by
RING-associated XIAP E3 ligase (Lewis et al., 2004), Smad4
signaling (Birkey Reffey et al., 2001), negative modulation by
XIAP-binding proteins (Resch et al., 2009), or phosphorylation-
induced degradation of IkBa, at least in endothelial cells (Ho-
fer-Warbinek et al., 2000). Here, reconstitution experiments in
XIAP/ cells, together with add-back studies using wild-type
or mutant recombinant proteins, demonstrated that NF-kB
activation requires the assembly of a survivin-XIAP intermolec-
ular complex. Structurally, this may favor the recruitment of the
adaptor protein, TAB1 (Lu et al., 2007), resulting in downstream
activation of the IKK kinase, TAK1, and IkBa phosphorylation(Hofer-Warbinek et al., 2000). Accordingly, a V80D XIAP mutant
defective in TAB1 binding (Lu et al., 2007) did not cooperate with
survivin in NF-kB activation. However, additional requirements
of a survivin-XIAP complex likely contribute to this response,
because RING-less XIAP, or a Lys467Ala XIAP mutant that abol-
ishes E3 ligase activity, also failed to synergize with survivin in
stimulating NF-kB (T.D. and D.C.A., unpublished data), in agree-
ment with previous findings (Lewis et al., 2004). Broadly, IAP
heterodimerization may function as general mechanism of
cellular homeostasis (Srinivasula and Ashwell, 2008), because
a survivin-BRUCE complex may regulate cytokinesis (Pohl and
Jentsch, 2008), and a survivin-XIAP interaction (Dohi et al.,
2007) opposes tumor cell apoptosis by enhancing XIAP stability
and synergistically inhibiting caspases (Dohi et al., 2004).
Previously, a link between NF-kB activity and metastasis has
been tied to stimulation of epithelial-mesenchymal transition
(EMT), expression of matrix metalloproteinase (MMP)–9, or
repression of putative metastasis-suppressor genes (Naugler
and Karin, 2008). Here, IAP activation of NF-kB did not result in
morphological features of EMT, as judged by the unchanged
levels of E-cadherin or MMP-2 or -9 (S.M. and D.C.A., unpub-
lished observations). Conversely, NF-kB activity under these
conditions contributed to a broad ‘‘adhesion gene signature’’
in tumor cells, characterized by a several hundred fold upregula-
tion of fibronectin. There is evidence that this pathwaymay occur
during tumor progression in vivo, because transgenic mice
expressing survivin in the urinary bladder exhibited a similar
adhesion gene signature linked to aggressive tumor behavior
and abbreviated survival (Salz et al., 2005). Correlative observa-
tions in humans seem consistent with this scenario, because
fibronectin is overexpressed in various epithelial malignancies
(Bittner et al., 2000) and linked to disease dissemination (Clark
et al., 2000) and shortened overall and disease-free survival
(Yao et al., 2007). Several mechanistic models have been
proposed to explain these findings, and elevated levels of fibro-
nectin have been linked to loss of epithelial polarity (Nelson and
Bissell, 2006), increased tissue rigidity (Paszek et al., 2005),
disruption of mammary acinar morphogenesis (Williams et al.,
2008), resistance to hormonal therapy (Helleman et al., 2008),
and formation of a metastatic niche (Kaplan et al., 2005).
The data presented here suggest a broader scenario, estab-
lishing fibronectin as a direct mediator of tumor cell invasion.
This process is postulated to involve a paracrine/autocrine
signaling circuitry (Figure 8), in which fibronectin overproduced
and released extracellularly by IAP-expressing tumor cells binds
back to the cell surface, engaging cognate b1 integrins and trig-
gering cell- and matrix-autonomous activation of cell motility
kinases FAK and Src (Figure 8). Accordingly, outside-in signaling
mediated by b1 integrins (Ginsberg et al., 2005) leads to phos-
phorylation of Src (Mitra and Schlaepfer, 2006) and FAK (Sieg
et al., 2000) and mediates tumor cell invasion in vivo (Parsons
et al., 2008). Although antibody inhibition studies demonstrated
that b1 integrins are essential for IAP-mediated tumor cell
invasion, immunologic or molecular targeting of fibronectin
was only partially (i.e., 50%) effective, suggesting that other b1
integrin ligands up-regulated in IAP-expressing cells (e.g.,
collagen isoforms) cooperate in this response.
The ability of this autocrine/paracrine signaling circuit (Figure 8)
to counter anoikis likely provides an additional advantage forCancer Cell 17, 53–64, January 19, 2010 ª2010 Elsevier Inc. 61
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Survivin-XIAP Signaling in Metastasismetastasis. Detachment of epithelial cells from the extracellular
matrix (Frisch and Screaton, 2001), as well as unligation of so-
called dependence receptors (Bredesen et al., 2005), is normally
followed by apoptosis, but many tumor cell types manage to
escape this response, and their ability to remain viable in
suspension is thought to favor hematogenous or lymphatic
dissemination (Nguyen and Massague, 2007). The requirements
of transformed cells to counter anoikis have not been completely
elucidated, and a potential protective role of IAPs in this process,
mostly XIAP, has been linked to caspase inhibition (Liu et al.,
2006). At variance with this paradigm, IAP inhibition of anoikis
did not involve release of survivin from mitochondria, which is
required for cytoprotection (Dohi et al., 2007), but rather b1 integ-
rin/fibronectin-mediated phosphorylation of FAK and Src
kinases, thus similar to the paradigm of IAP-mediated tumor
cell motility (Figure 8). This is in line with a protective role of these
molecules against mitochondrial dysfunction during anoikis,
potentially via activation of PI3 kinase/Akt-mediated cell survival
(Bouchard et al., 2008). This pathway was selective for anoikis,
because overexpression of survivin in transformed cells did not
confer a further advantage for anchorage-independent cell
growth, an observation consistent with the ability of activated
FAK to attenuate oncogene-mediated colony formation in soft
agar (Moissoglu and Gelman, 2003).
When tested in an in vivo model that recapitulates many of the
steps of the metastatic process, unaffected by primary tumor
growth, IAP signaling promoted rapid and extensive metastatic
dissemination to the liver. Retrospective analysis of patient
series identified IAPs, especially survivin, as contributors to
tumor progression (Hinnis et al., 2007), but a role for these mole-
cules as metastasis genes had not been previously postulated.
Although metastasis of Ras-transformed fibroblasts has been
recently linked to FAK dephosphorylation (Zheng et al., 2009),
the IAP pathway of tumor cell dissemination occurred indistin-
guishably in tumor types with wild-type or mutant Ras and was
associated with phosphorylation of FAK in metastatic foci
in vivo. Importantly, the cytoprotective functions of survivin or
XIAP were not required for IAP-mediated metastasis. Accord-
ingly, overexpression of noncytoprotective survivin in INS-1 cells
(Dohi et al., 2007), or reconstitution of XIAP-deficient HCT116
cells with a D143A/W310A XIAP mutant that does not bind
caspases (Lewis et al., 2004), mediated tumor cell invasion
in vitro and promoted extensive liver metastasis in vivo. In
addition, expression of antiapoptotic Bcl-2 could not substitute
for IAP signaling in metastasis, suggesting that suppression of
cell death alone is insufficient to confer a successful metastatic
phenotype in vivo. These data are consistent with previous
observations that IAP activation of NF-kB (Lu et al., 2007) is
separable from its role in caspase inhibition (Lewis et al., 2004)
and that metastatic dissemination in a transgenic model of
melanoma does not require survivin cytoprotection (Thomas
et al., 2007).
In summary, we identified IAPs as direct metastasis genes,
orchestrating a cellular network of NF-kB-dependent gene
expression, b1 integrin signaling, and activation of FAK and
Src kinases required for metastatic dissemination (Figure 8).
Although IAPs are not easily ‘‘drugable’’ targets in cancer,
molecular antagonists of both XIAP and survivin have been
developed and produced some encouraging patient responses62 Cancer Cell 17, 53–64, January 19, 2010 ª2010 Elsevier Inc.in early-phase clinical trials (Altieri, 2008). The data presented
here suggest that these agents may not have overlapping
specificities and could be differentially utilized as individualized
therapeutic regimens in patients with cancer. Accordingly,
Smac mimetics XIAP antagonists may be predicted to activate
apoptosis in tumors (Varfolomeev et al., 2007) but would not
interfere with IAP signaling, which plays a pivotal role in tumor
progression and metastasis (present study). Conversely, agents
that directly suppress the levels of XIAP and survivin in tumors,
including antisense molecules and transcriptional repressors
of the survivin gene, which are also being tested in early phase
clinical trials (Altieri, 2008), could be rationally tested as first-in-
class antimetastatic regimens in patients with advanced and
metastatic disease.EXPERIMENTAL PROCEDURES
Cell Migration and Invasion
Analysis of cell migration was performed using 6.5 mm Transwell chambers
(8 mmpore size; Costar). Inserts were prepared by coating the upper and lower
surfaces with 15 mg/ml collagen (Cohesion, Palo Alto, CA) for 18 hr at 4C,
followed by a blocking step with DMEM containing 0.25% heat-inactivated
BSA for 1 hr at 37C. In some experiments, Transwell inserts were left
uncoated. The various cell types were harvested, suspended in DMEM con-
taining 0.25% heat-inactivated BSA, and added (1 3 105) to the upper
chamber, with aliquots of conditioned medium collected from NIH 3T3 fibro-
blasts placed in the lower chamber as chemoattractant. After 1 hr of incuba-
tion, nonmigrating cells were removed mechanically from the upper chamber
using a cotton swab. Cells migrated to the lower surface of the Transwell
membrane were fixed in methanol for 10 min at 22C, and membranes were
mounted on glass slides using Vectashield mounting medium containing
DAPI (Vector Laboratories, Burlingame, CA). Cell migration was quantified
by counting the number of stained nuclei in five individual fields in each Trans-
well membrane, by fluorescence microscopy, in duplicate.
For analysis of cell invasion, the upper Transwell chamber (8 mm pore size;
Costar) was coated with 5 mg Matrigel (Collaborative Research, Bedford, MA)
diluted in cold water and was allowed to air dry. After 1 hr of incubation with
DMEM, the various cell types (1 3 105) were added to the upper chamber
for 6–24 hr at 37C. Cells that had invaded the lower surface of the membrane
were fixed with methanol, stained with DAPI, and quantified by fluorescence
microscopy. In some experiments, cells were incubated with the following
pharmacologic inhibitors of Src (PP-2, 50 mM; SU6656, 25–50 mM), MEK
(PD98059, 50 mM, or U0126, 25 mM), PI3 kinase (LY290042, 50 mM), or vehicle
(DMSO) for 1 hr at 37C, added to Matrigel-coated membranes, and analyzed
for cell invasion by fluorescence microscopy.
In Vivo Metastasis Model
All experiments involving animals were approved by an Institutional Animal
Care and Use Committee. Female SCID/beige mice (6–8 weeks old) were
anesthetized with ketamine hydrochloride, the abdominal cavity was exposed
by laparotomy, and animals were injected in the spleen with 2 3 106 MCF-7,
MCF-7 SVV, or MCF-7 SVV cells carrying stable shRNA knockdown of XIAP
(MCF-7 SVV-XIAP KD) stably transfected with a luciferase cDNA. To avoid
potential confounding effects onmetastasis due to variable growth of a primary
tumor, the spleen was removed 24 hr after injection of the tumor cells. The
incision was closed in two layers with vicryl 5/0 and wound clips. On days 1,
3, 7, and 11 after injection, animals were analyzed for metastatic disease by
bioluminescence imaging using an IVIS-100 camera system for detection of
luciferase expression (Xenogen, Alameda, CA). Briefly, mice were anesthe-
tized with isoflurane and intraperitoneally injected with 2.2 mg of luciferin
sodium salt (GOLD Bio Technology, Inc.) in PBS (pH 7.4). During image acqui-
sition, isoflurane anesthesia was maintained using a nose cone delivery
system. Both supine and prone images were scanned for a 3-min acquisition
interval. Each image was acquired sequentially three to four times, and data
were collected at the time of peak luminescence. The bioluminescence images
Cancer Cell
Survivin-XIAP Signaling in Metastasiswere overlaid on black and white photographs of the mice collected at the
same time. Signal intensity was quantified as the sum of all detected photon
counts within a region of interest using Living image software (Xenogen,
version 2.50). On day 11, all mice in the various groups were sacrificed, and
their livers were resected and quantified for bioluminescence intensity ex
vivo. In some experiments, wild-type (XIAP+/+), XIAP/, or XIAP/ HCT116
cells stably transfected with D143A/W310A XIAP mutant (Lewis et al., 2004)
lacking antiapoptotic function (5 animals/group), were injected (5 3 106 cells)
in the spleen of SCID/beige mice, followed by splenectomy as described
above. Animals were sacrificed after 3 weeks, and livers were analyzed
histologically. In other experiments, wild-type INS-1 cells (four animals) or
INS-1 stably transfected with survivin (6 animals) that is not cytoprotective in
this cell type (Dohi et al., 2007) or Bcl-2 (5 animals) were injected (53 106 cells)
in the spleen of SCID/beige mice, followed by splenectomy 1 day after recon-
stitution. Mice were monitored for blood glucose content twice weekly and
were sacrificed after 3 weeks for histologic examination of livers.
Histology
Livers from the various animal groups were fixed in buffered formalin and
embedded in paraffin. For insulin staining, sections were deparaffinized,
rehydrated in water, and quenched for endogenous peroxidase. Epitope
heat retrieval was performed by steaming the slides in 10% sodium citrate
for 20 min. Processed slides were rinsed in PBS (pH 7.4) and stained with
an antibody to insulin using standard avidin-biotin-peroxidase technique
(Histostain-plus, Zymed Laboratories). Slides were incubated with DAB as a
chromogen and were counterstained with hematoxylin. Control sections
were processed as above with nonbinding IgG, and resulted in no detectable
staining.
Statistical Analysis
Data were analyzed using the unpaired t test on aGraphPad software package
for Windows (Prism 4.0). A p value of 0.05 was considered as statistically
significant.
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